Diabetes

Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials

  • 1.

    Lee, A. K. et al. The Association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 41, 104–111. https://doi.org/10.2337/dc17-1669 (2018).

    Article 
    PubMed 

    Google Scholar
     

  • 2.

    Aucott, L. S. et al. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open 6, e010836. https://doi.org/10.1136/bmjopen-2015-010836 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 3.

    Kanters, S. D., Banga, J. D., Stolk, R. P. & Algra, A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc. Med. 4, 67–75. https://doi.org/10.1177/1358836×9900400203 (1999).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 4.

    Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139. https://doi.org/10.1056/NEJMoa0808431 (2009).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 5.

    Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559. https://doi.org/10.1056/NEJMoa0802743 (2008).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 6.

    Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572. https://doi.org/10.1056/NEJMoa0802987 (2008).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 7.

    Turner, R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854–865 (1998).

  • 8.

    Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322. https://doi.org/10.1056/NEJMoa1603827 (2016).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 9.

    Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128. https://doi.org/10.1056/NEJMoa1504720 (2015).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 10.

    Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657. https://doi.org/10.1056/NEJMoa1611925 (2017).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 11.

    Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844. https://doi.org/10.1056/NEJMoa1607141 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 12.

    12Association, A. D. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 (2020). doi:10.2337/dc20-S009

  • 13.

    Pfeffer, M. A. et al. Lixisenatide in patients with type 2
    diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257. https://doi.org/10.1056/NEJMoa1509225 (2015).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 14.

    Ratner, R. et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc. Diabetol. 10, 22. https://doi.org/10.1186/1475-2840-10-22 (2011).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 15.

    Davies, M. J. , & Management of Hyperglycemia in Type 2 Diabetes, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(2669–2701), 2018. https://doi.org/10.2337/dci18-0033 (2018).

    Article 

    Google Scholar
     

  • 16.

    Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535. https://doi.org/10.1136/bmj.b2535 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 17.

    17Higgins, J. P. T. & Green, S. Cochrane handbook for systematic reviews of interventions. In The Cochrane Collaboration (2011).

  • 18.

    Higgins, J. P. et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928. https://doi.org/10.1136/bmj.d5928 (2011).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    19GRADEpro GDT: GRADEpro Guideline Development Tool [Software] (2015). https://gradepro.org.

  • 20.

    Turner, R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).

  • 21.

    Begg, C. B. & Berlin, J. A. Publication bias: a problem in interpreting medical data. J. R. Stat. Soc. Ser. A (Stat. Soc.) 151, 419–463. https://doi.org/10.2307/2982993 (1988).

    Article 

    Google Scholar
     

  • 22.

    Sterne, J. A. C., Egger, M. & Smith, G. D. Investigating and dealing with publication and other biases in meta-analysis. BMJ 323, 101–105 (2001).

    CAS 
    Article 

    Google Scholar
     

  • 23.

    23Borenstein, M., Hedges, L. V., Higgins, J. P. T. & Rothstein, H. R. In Introduction to Meta‐Analysis Vol. 1 Ch. 21 (Wiley, 2009).

  • 24.

    Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443. https://doi.org/10.1056/NEJMoa066224 (2006).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 25.

    Pratley, R. et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet https://doi.org/10.1016/s0140-6736(19)31271-1 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • 26.

    Holman, R. R. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361, 1736–1747. https://doi.org/10.1056/NEJMoa0905479 (2009).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 27.

    Gilbert, R. E. & Krum, H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385, 2107–2117. https://doi.org/10.1016/s0140-6736(14)61402-1 (2015).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 28.

    Hanefeld, M., Frier, B. M. & Pistrosch, F. Hypoglycemia and cardiovascular risk: is there a major link?. Diabetes Care 39(Suppl 2), S205-209. https://doi.org/10.2337/dcS15-3014 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 29.

    Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321–1331. https://doi.org/10.1056/NEJMoa1506930 (2016).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 30.

    Rundek, T. et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch. Neurol. 67, 1195–1200. https://doi.org/10.1001/archneurol.2010.235 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 31.

    Palmer, S. C. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316, 313–324. https://doi.org/10.1001/jama.2016.9400 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 32.

    Zheng, S. L. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319, 1580–1591. https://doi.org/10.1001/jama.2018.3024 (2018).

    ADS 
    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    Wu, S. et al. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. Expert Opin. Drug. Saf. 17, 243–249. https://doi.org/10.1080/14740338.2018.1424826 (2018).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 34.

    Liu, J. et al. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357, j2499. https://doi.org/10.1136/bmj.j2499 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 35.

    Tang, H. et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus. Am. J. Cardiol. 118, 1774–1780. https://doi.org/10.1016/j.amjcard.2016.08.061 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 36.

    Boussageon, R. et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9, e1001204. https://doi.org/10.1371/journal.pmed.1001204 (2012).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 37.

    Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379, 633–644. https://doi.org/10.1056/NEJMoa1800256 (2018).

    Article 
    PubMed 

    Google Scholar
     

  • 38.

    Gregg, E. W. et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 4, 913–921. https://doi.org/10.1016/s2213-8587(16)30162-0 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Inzucchi, S. E. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41, 356–363. https://doi.org/10.2337/dc17-1096 (2018).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 40.

    Pc, L., Aj, S., Kr, A. & Dr, J. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J. Clin. Epidemiol. https://doi.org/10.1016/s0895-4356(01)00414-0 (2002).

    Article 

    Google Scholar
     

  • 41.

    Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366, 1279–1289. https://doi.org/10.1016/s0140-6736(05)67528-9 (2005).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 42.

    Mazzone, T. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296, 2572–2581. https://doi.org/10.1001/jama.296.21.joc60158 (2006).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 43.

    Nauck, M. A., Meininger, G., Sheng, D., Terranella, L. & Stein, P. P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9, 194–205. https://doi.org/10.1111/j.1463-1326.2006.00704.x (2007).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 44.

    Dargie, H. J. et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol. 49, 1696–1704. https://doi.org/10.1016/j.jacc.2006.10.077 (2007).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 45.

    Chan, J. C. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545–555. https://doi.org/10.1111/j.1463-1326.2008.00914.x (2008).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 46.

    Home, P. D. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125–2135. https://doi.org/10.1016/s0140-6736(09)60953-3 (2009).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 47.

    Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616–625. https://doi.org/10.1001/archinternmed.2009.20 (2009).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 48.

    Bertrand, O. F. et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 211, 565–573. https://doi.org/10.1016/j.atherosclerosis.2010.06.005 (2010).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 49.

    Gaziano, J. M. et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33, 1503–1508. https://doi.org/10.2337/dc09-2009 (2010).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 50.

    Giles, T. D., Elkayam, U., Bhattacharya, M., Perez, A. & Miller, A. B. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest. Heart Fail. 16, 111–117. https://doi.org/10.1111/j.1751-7133.2010.00154.x (2010).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 51.

    Matthews, D. R. et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 12, 780–789. https://doi.org/10.1111/j.1463-1326.2010.01233.x (2010).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 52.

    Gallwitz, B. et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 379, 2270–2278. https://doi.org/10.1016/s0140-6736(12)60479-6 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 53.

    Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475–483. https://doi.org/10.1016/s0140-6736(12)60691-6 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 54.

    Garber, A. J. et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1498–1507. https://doi.org/10.1016/s0140-6736(12)60205-0 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 55.

    Gerstein, H. C. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319–328. https://doi.org/10.1056/NEJMoa1203858 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 56.

    Zinman, B. et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 35, 2464–2471. https://doi.org/10.2337/dc12-1205 (2012).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 57.

    Cefalu, W. T. et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950. https://doi.org/10.1016/s0140-6736(13)60683-2 (2013).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 58.

    Hong, J. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36, 1304–1311. https://doi.org/10.2337/dc12-0719 (2013).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 59.

    Scirica, B. M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317–1326. https://doi.org/10.1056/NEJMoa1307684 (2013).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 60.

    White, W. B. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327–1335. https://doi.org/10.1056/NEJMoa1305889 (2013).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 61.

    Ridderstrale, M. et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2, 691–700. https://doi.org/10.1016/s2213-8587(14)70120-2 (2014).

    Article 
    PubMed 

    Google Scholar
     

  • 62.

    Blonde, L. et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 385, 2057–2066. https://doi.org/10.1016/s0140-6736(15)60936-9 (2015).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 63.

    Giorgino, F., Benroubi, M., Sun, J. H., Zimmermann, A. G. & Pechtner, V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (award-2). Diabetes Care 38, 2241–2249. https://doi.org/10.2337/dc14-1625 (2015).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 64.

    Green, J. B. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232–242. https://doi.org/10.1056/NEJMoa1501352 (2015).

    ADS 
    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 65.

    Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239. https://doi.org/10.1056/NEJMoa1612917 (2017).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 66.

    Marso, S. P. et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med. 377, 723–732. https://doi.org/10.1056/NEJMoa1615692 (2017).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 67.

    Vaccaro, O. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 10, 15–20. https://doi.org/10.1016/s2213-8587(17)30317-0 (2017).

    Article 

    Google Scholar
     

  • 68.

    Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529. https://doi.org/10.1016/s0140-6736(18)32261-x (2018).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 69.

    Rosenstock, J. et al. Effect of Linagliptin vs Placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69–79. https://doi.org/10.1001/jama.2018.18269 (2019).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 70.

    Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet https://doi.org/10.1016/s0140-6736(19)31149-3 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • 71.

    Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1901118 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • 72.

    Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306. https://doi.org/10.1056/NEJMoa1811744 (2019).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 73.

    Pieber, T. R. et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 7, 528–539. https://doi.org/10.1016/s2213-8587(19)30194-9 (2019).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 74.

    Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357. https://doi.org/10.1056/NEJMoa1812389 (2019).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • 75.

    Rosenstock, J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA https://doi.org/10.1001/jama.2019.13772 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Via Source link

    Most Popular

    Safety Health News Provides information on HEALTH NEWS, HEALTH CARE, WOMEN’S HEALTH, KID’S HEALTH, MEN’S HEALTH, DIABETES & DEALS NEWS

    All About information only. Please consult your Doctor for any illness.

    Copyright © 2020 Safety Health News. Powered by Wordpress.

    To Top